Hims & Hers Health: Buy The Novo Nordisk Drama Dip
The Hims & Hers Health investment thesis remains intact, despite the Novo Nordisk partnership ending, due to not being focused on branded GLP-1s. The company has long-term business targets, including $6.5B in 2030 revenue, are driven by personalized services, global expansion, and not dependent on branded drug deals. The ZAVA acquisition and European expansion offset any short-term disruption, boosting the subscriber base by over 50% and opening new markets.
HIMZ: Buy For Short-Term Gains On Hims & Hers Health, But Be Wary Of The Risks
HIMZ offers 2x leveraged exposure to HIMS, ideal for high-risk, short-term traders seeking amplified volatility, not long-term investors. Recent HIMS volatility, including the Novo Nordisk partnership fallout, creates attractive trading opportunities for nimble investors using HIMZ. HIMS continues to innovate and expand, targeting new markets and launching products, leading to strong growth potential and future catalysts.
Hims & Hers Health (HIMS) Loses 22.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Hims & Hers Health (HIMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers: Panic Sell Or Opportunistic Buy?
The Hims & Hers and Novo Nordisk "long-term collaboration" has ended up in flames within a couple of months, causing steep declines in both stocks. In this report, we discuss the breakup and assess the potential impact on Hims & Hers. After a 35% crash in a single session, is HIMS stock a Buy, Sell, or Hold? Read on to learn more.
Hims & Hers: The Novo Nordisk Breakup Changes Nothing
The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a GLP-1 play. HIMS' core value lies in its broad treatment offerings and disruptive model, not in partnerships with big pharma like NVO. Legal risks remain, but I believe HIMS is well-positioned to defend itself, and no legal action has been initiated by NVO yet.
Hims & Hers stock plummets after Novo Nordisk ends partnership over ‘knockoff' Wegovy
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers' “knockoff” weight-loss drugs. Now, Hims & Hers' shares are plummeting as investors react to the news.
Why Hims & Hers Stock Could Be a Multi-Bagger in the Making
It's not often that investors come across the kind of companies that can yield a multi-bagger investment over the years. Still, today, there is one name that possesses all the right components (and timing) to make it a suitable investment for those seeking to compound their wealth in the coming years.
HIMS Stock To $25?
Hims & Hers Health (NASDAQ: HIMS) experienced a devastating 35% stock crash on June 23, 2025, after Novo Nordisk abruptly terminated their brief partnership. The dramatic sell-off reflects not just the immediate loss of a key business relationship, but fundamental questions about the company's long-term viability in the weight-loss drug market.
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $41.98, signifying a -34.63% move from its prior day's close.
HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?
Hims & Hers Health ( HIMS ) has been one of the market's standout growth stocks in recent years. The company has successfully built a direct-to-consumer health platform targeting conditions like hair loss, mental health, and more recently, weight loss—delivering very strong revenue growth and stock returns.
Weight Loss Woes: Hims & Hers (HIMS) Shares Under Pressure
Hims & Hers (HIMS) shares are reeling after Novo Nordisk (NVO) severs its weight-loss drug relationship with the telehealth company. NVO claims HIMS was marketing knock-off weight loss drugs using "deceptive promotion" tactics.
